CVS Health (NYSE:CVS) issued its earnings results on Thursday. The pharmacy operator reported $1.92 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.88 by $0.04, Bloomberg Earnings reports. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The business had revenue of $48.39 billion during the quarter, compared to analyst estimates of $47.54 billion. During the same quarter in the previous year, the firm earned $1.71 EPS. CVS Health’s revenue was up 5.3% on a year-over-year basis.

Shares of CVS Health (CVS) traded down $2.03 during trading hours on Thursday, hitting $72.32. The company had a trading volume of 7,551,143 shares, compared to its average volume of 9,004,552. The company has a market cap of $73,250.00, a P/E ratio of 14.99, a PEG ratio of 1.24 and a beta of 0.92. The company has a current ratio of 1.05, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67. CVS Health has a 52 week low of $66.45 and a 52 week high of $84.00.

The business also recently disclosed a quarterly dividend, which was paid on Friday, February 2nd. Investors of record on Wednesday, January 24th were paid a dividend of $0.50 per share. The ex-dividend date of this dividend was Tuesday, January 23rd. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.77%. CVS Health’s dividend payout ratio (DPR) is presently 41.32%.

A number of equities analysts have weighed in on CVS shares. Needham & Company LLC raised CVS Health from a “hold” rating to a “buy” rating and boosted their target price for the stock from $69.02 to $79.00 in a research report on Friday, November 10th. SunTrust Banks set a $85.00 price target on CVS Health and gave the company a “buy” rating in a research note on Thursday, October 12th. Mizuho set a $90.00 price target on CVS Health and gave the company a “buy” rating in a research note on Tuesday, October 24th. Cowen set a $86.00 price target on CVS Health and gave the company a “buy” rating in a research note on Sunday, October 29th. Finally, Deutsche Bank initiated coverage on CVS Health in a research note on Monday, December 4th. They set a “buy” rating and a $90.00 price target for the company. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, eleven have issued a buy rating and three have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $88.27.

In related news, EVP Lisa Bisaccia sold 29,445 shares of the business’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total value of $2,208,375.00. Following the transaction, the executive vice president now directly owns 15,556 shares of the company’s stock, valued at approximately $1,166,700. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.61% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Pathstone Family Office LLC raised its holdings in shares of CVS Health by 341.0% during the 2nd quarter. Pathstone Family Office LLC now owns 1,270 shares of the pharmacy operator’s stock worth $2,353,000 after acquiring an additional 982 shares in the last quarter. Wealthcare Advisory Partners LLC raised its holdings in shares of CVS Health by 330.3% during the 3rd quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock worth $105,000 after acquiring an additional 991 shares in the last quarter. Fieldpoint Private Securities LLC raised its holdings in shares of CVS Health by 333.3% during the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after acquiring an additional 1,000 shares in the last quarter. Arcadia Investment Management Corp MI raised its holdings in shares of CVS Health by 119.6% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after acquiring an additional 726 shares in the last quarter. Finally, MPS Loria Financial Planners LLC purchased a new stake in shares of CVS Health during the 2nd quarter worth approximately $119,000. 81.69% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dailypolitical.com/2018/02/08/cvs-health-cvs-announces-earnings-results.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Earnings History for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.